glp-1 discovery receptor assay: drug in the metabolic field JCI - The GLP-1 journey:

You can dissolve these lozenges on your tongue or chew them

Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming

In April 2024, the Federal Trade Commission announced that it was expanding its campaign against pharmaceutical manufacturers improper or inaccurate listing of patents in the Food and Drug Administrations (FDA) Orange Book, disputing junk patent listings for diabetes, weight loss, asthma, and COPD drugs, including Novo Nordisk Inc.s blockbuster weight-loss drug, Ozempic. If the administration revoked Novos extension, patent protection for semaglutide will expire in 2026 as it is scheduled to do in many other countries

& Keefe, D

Role of prolidase activity and oxidative stress biomarkers in unexplained infertility

Nevertheless, it is increasingly evident that the antiinflammatory actions of GLP-1 and related mimetics represent key biological effects of agonizing the GLP-1 receptor, and these findings are considered to be of direct relevance to the renoprotective effects seen with GLP-1 mimetics